December 10, 2010 – The first commercial production of generators using molybdenum-99 (Mo-99) produced with low-enriched uranium (LEU) targets in the United States is underway. The Lantheus TechneLite (Technetium Tc99m) generator received the first commercial scale batch from NTP Radioisotopes, a subsidiary of the Nuclear Energy Corporate of South Africa (NESCA)

As part of the Global Threat Reduction Initiative, the company is working to convert the production of Mo-99, an important medical isotope, from highly-enriched uranium (HEU) to LEU.

Lantheus is the first company in North America to receive FDA approval for the commercial sale of generators that produce Mo-99 from LEU targets.

Mo-99 is the parent isotope of technetium-99m (Tc-99m), the most widely used radioisotope in the world for molecular and nuclear diagnostic imaging tests. Tc-99m is a critical component of many medical tests, including scans of the heart, brain, kidneys and some types of tumors. In diagnostic use, Tc-99m is attached to a specific molecule and injected into the patient, where it emits gamma radiation that can be used to produce an image of the area.

For more information: www.lantheus.com


Additional Content

News | SNMMI

The Society of Nuclear Medicine and Molecular Imaging's (SNMMI) 2026 Annual Meeting will take place May 30–June 2 in Los ...

Time April 07, 2026
arrow
News | PET Imaging

March 25, 2026 — Catalyst MedTech, a provider of nuclear medicine and molecular imaging solutions, has announced it is ...

Time April 06, 2026
arrow
News | FDA

March 18, 2026 — FluoGuide A/S, a biotech company maximizing surgical outcomes in oncology, has announced that the U.S ...

Time March 24, 2026
arrow
News | Radiology Education

March 17, 2026 – The Center for Radiology Education (CRE) has announced a nationwide initiative to provide scholarships* ...

Time March 17, 2026
arrow
News | PET-CT

Feb. 27, 2026 — A new targeted PET/CT tracer can detect treatment response in rheumatoid arthritis patients in as little ...

Time February 26, 2026
arrow
Subscribe Now